MICOT PHARMA-B (02335): The research on XTL6001 has been accepted for presentation at EASD 2026 and ASN KIDNEY WEEK 2026.

MICOT PHARMA-B (02335) announced that the research results of one of its major products, XTL6001, have been accepted for presentation at multiple top-tier internationally recognized academic conferences in the fields of diabetes, metabolic diseases, and kidney diseases. Following its initial report at the ADA, further analyses will be presented at the upcoming EASD and ASN annual meetings. Two research abstracts related to XTL6001 have been accepted for presentation at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD 2026). The study titled XTL6001: a novel triple MasR/GCGR/GLP-1R agonist for weight loss and obesity-related complications has been selected for an oral presentation in the session titled Future obesity treatments in human trials, while the study XTL6001: a novel triple MasR/GCGR/GLP-1R agonist for chronic kidney disease/diabetic kidney disease with proteinuria and hyperuricaemia has been chosen for a brief oral discussion. Additionally, an abstract titled XTL6001: A Novel Triple MasR/GCGR/GLP-1 Receptor Agonist for Hyperuricemic Nephropathy has been accepted for poster presentation at the 2026 American Society of Nephrology Kidney Week (ASN Kidney Week 2026) in the session titled CKD: Mechanisms of Injury and Fibrosis1. The company believes that following the report of the research results related to XTL6001 at ADA 2026, the subsequent selections for oral presentations at EASD 2026 on weight management and CKD/DKD and for poster presentation at ASN Kidney Week 2026 on hyperuricemic nephropathy represent another important milestone in the development of XTL6001. The selection of XTL6001s research for presentation at major international academic conferences in diabetes/metabolic and kidney disease fields highlights its differentiated development profile beyond weight management and underscores the potential renal protective effects associated with its innovative GLP-1R/GCGR/MasR triple-target mechanism, distinguishing XTL6001 from traditional GLP-1-based therapies.